JP6938796B2 - 眼疾患を治療するための方法 - Google Patents

眼疾患を治療するための方法 Download PDF

Info

Publication number
JP6938796B2
JP6938796B2 JP2020547357A JP2020547357A JP6938796B2 JP 6938796 B2 JP6938796 B2 JP 6938796B2 JP 2020547357 A JP2020547357 A JP 2020547357A JP 2020547357 A JP2020547357 A JP 2020547357A JP 6938796 B2 JP6938796 B2 JP 6938796B2
Authority
JP
Japan
Prior art keywords
vegf antagonist
weeks
patient
dose
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020547357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021509912A (ja
JP2021509912A5 (https=
Inventor
ラシーヌ，エイミー
ヴァイクセルベルガー，アンドレアス
ワーバートン，ジェイムス
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021509912A publication Critical patent/JP2021509912A/ja
Publication of JP2021509912A5 publication Critical patent/JP2021509912A5/ja
Priority to JP2021142541A priority Critical patent/JP2021191778A/ja
Application granted granted Critical
Publication of JP6938796B2 publication Critical patent/JP6938796B2/ja
Priority to JP2023212445A priority patent/JP2024042697A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020547357A 2018-03-16 2019-03-08 眼疾患を治療するための方法 Active JP6938796B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021142541A JP2021191778A (ja) 2018-03-16 2021-09-01 眼疾患を治療するための方法
JP2023212445A JP2024042697A (ja) 2018-03-16 2023-12-15 眼疾患を治療するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643887P 2018-03-16 2018-03-16
US62/643,887 2018-03-16
US201962805344P 2019-02-14 2019-02-14
US62/805,344 2019-02-14
PCT/IB2019/051899 WO2019175727A1 (en) 2018-03-16 2019-03-08 Methods for treating ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142541A Division JP2021191778A (ja) 2018-03-16 2021-09-01 眼疾患を治療するための方法

Publications (3)

Publication Number Publication Date
JP2021509912A JP2021509912A (ja) 2021-04-08
JP2021509912A5 JP2021509912A5 (https=) 2021-05-20
JP6938796B2 true JP6938796B2 (ja) 2021-09-22

Family

ID=66049363

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020547357A Active JP6938796B2 (ja) 2018-03-16 2019-03-08 眼疾患を治療するための方法
JP2021142541A Withdrawn JP2021191778A (ja) 2018-03-16 2021-09-01 眼疾患を治療するための方法
JP2023212445A Withdrawn JP2024042697A (ja) 2018-03-16 2023-12-15 眼疾患を治療するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021142541A Withdrawn JP2021191778A (ja) 2018-03-16 2021-09-01 眼疾患を治療するための方法
JP2023212445A Withdrawn JP2024042697A (ja) 2018-03-16 2023-12-15 眼疾患を治療するための方法

Country Status (11)

Country Link
US (1) US20210017266A1 (https=)
EP (1) EP3765083A1 (https=)
JP (3) JP6938796B2 (https=)
KR (2) KR20200131839A (https=)
CN (1) CN111867631A (https=)
AU (2) AU2019235577B2 (https=)
CA (1) CA3091096A1 (https=)
IL (2) IL277333B2 (https=)
MX (1) MX2020009140A (https=)
TW (1) TWI727279B (https=)
WO (1) WO2019175727A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024042697A (ja) * 2018-03-16 2024-03-28 ノバルティス アーゲー 眼疾患を治療するための方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
PE20211602A1 (es) 2018-12-18 2021-08-18 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
CN116195003A (zh) * 2020-09-23 2023-05-30 基因泰克公司 对黄斑水肿患者的注射频率的机器学习预测
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
PE20260040A1 (es) 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
PE20181363A1 (es) * 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
KR20200131839A (ko) * 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024042697A (ja) * 2018-03-16 2024-03-28 ノバルティス アーゲー 眼疾患を治療するための方法

Also Published As

Publication number Publication date
CA3091096A1 (en) 2019-09-19
MX2020009140A (es) 2020-09-28
AU2021286278A1 (en) 2022-01-20
AU2021286278C1 (en) 2024-05-23
AU2021286278B2 (en) 2023-09-14
IL277333B1 (en) 2025-11-01
IL277333A (en) 2020-10-29
JP2021191778A (ja) 2021-12-16
RU2020133816A (ru) 2022-04-18
RU2020133816A3 (https=) 2022-04-18
JP2021509912A (ja) 2021-04-08
US20210017266A1 (en) 2021-01-21
EP3765083A1 (en) 2021-01-20
JP2024042697A (ja) 2024-03-28
CN111867631A (zh) 2020-10-30
TWI727279B (zh) 2021-05-11
KR20260036043A (ko) 2026-03-13
AU2019235577A1 (en) 2020-08-27
AU2019235577B2 (en) 2021-09-30
WO2019175727A1 (en) 2019-09-19
KR20200131839A (ko) 2020-11-24
IL277333B2 (en) 2026-03-01
TW201945027A (zh) 2019-12-01
IL323849A (en) 2025-12-01

Similar Documents

Publication Publication Date Title
JP6938796B2 (ja) 眼疾患を治療するための方法
US20260098085A1 (en) Methods for treating age-related macular degeneration
JP7828274B2 (ja) 眼疾患を治療するための方法
RU2776850C2 (ru) Способы лечения глазных заболеваний
JP2026072102A (ja) 眼疾患を治療するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210122

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210122

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210901

R150 Certificate of patent or registration of utility model

Ref document number: 6938796

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250